All Comments by Edward Koo

  1. Alpha-synuclein-immunoreactive deposits in human and animal prion diseases.
  2. Peeling plaque. Researchers remain optimistic about a vaccine against Alzheimer's.
  3. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction.
  4. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide.
  5. Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc.
  6. Copernicus revisited: amyloid beta in Alzheimer's disease.
  7. Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease.
  8. Endoplasmic reticulum stress-induced cysteine protease activation in cortical neurons: effect of an Alzheimer's disease-linked presenilin-1 knock-in mutation.
  9. Absence of cognitive impairment or decline in preclinical Alzheimer's disease.
  10. Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains.
  11. Head circumference and incident Alzheimer's disease: modification by apolipoprotein E.
  12. Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins.
  13. FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex.
  14. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice.
  15. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.